Biomark Diagnostics Stock Performance
| BMKDF Stock | USD 0.15 0.01 6.25% |
The firm shows a Beta (market volatility) of -0.81, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning BioMark Diagnostics are expected to decrease at a much lower rate. During the bear market, BioMark Diagnostics is likely to outperform the market. At this point, BioMark Diagnostics has a negative expected return of -0.45%. Please make sure to confirm BioMark Diagnostics' total risk alpha and the relationship between the kurtosis and period momentum indicator , to decide if BioMark Diagnostics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days BioMark Diagnostics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unfluctuating performance in the last few months, the Stock's fundamental indicators remain nearly stable which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
| Begin Period Cash Flow | 877.7 K | |
| Total Cashflows From Investing Activities | -59.2 K |
BioMark |
BioMark Diagnostics Relative Risk vs. Return Landscape
If you would invest 22.00 in BioMark Diagnostics on September 12, 2024 and sell it today you would lose (7.00) from holding BioMark Diagnostics or give up 31.82% of portfolio value over 90 days. BioMark Diagnostics is currently producing negative expected returns and takes up 5.2318% volatility of returns over 90 trading days. Put another way, 46% of traded pink sheets are less volatile than BioMark, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
BioMark Diagnostics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for BioMark Diagnostics' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as BioMark Diagnostics, and traders can use it to determine the average amount a BioMark Diagnostics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.087
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BMKDF |
Estimated Market Risk
| 5.23 actual daily | 46 54% of assets are more volatile |
Expected Return
| -0.45 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.09 actual daily | 0 Most of other assets perform better |
Based on monthly moving average BioMark Diagnostics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of BioMark Diagnostics by adding BioMark Diagnostics to a well-diversified portfolio.
BioMark Diagnostics Fundamentals Growth
BioMark Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of BioMark Diagnostics, and BioMark Diagnostics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BioMark Pink Sheet performance.
| Return On Asset | -1.45 | |||
| Operating Margin | (15.72) % | |||
| Current Valuation | 12.8 M | |||
| Shares Outstanding | 83.29 M | |||
| Price To Earning | (8.80) X | |||
| Price To Sales | 105.81 X | |||
| Revenue | 43.93 K | |||
| EBITDA | (1.22 M) | |||
| Cash And Equivalents | 364.96 K | |||
| Total Debt | 96.3 K | |||
| Book Value Per Share | (0.01) X | |||
| Cash Flow From Operations | (1.2 M) | |||
| Earnings Per Share | (0.01) X | |||
| Total Asset | 1.47 M | |||
| Retained Earnings | (3.47 M) | |||
| Current Asset | 19 K | |||
| Current Liabilities | 480 K | |||
About BioMark Diagnostics Performance
By analyzing BioMark Diagnostics' fundamental ratios, stakeholders can gain valuable insights into BioMark Diagnostics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if BioMark Diagnostics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if BioMark Diagnostics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
BioMark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions to detect, monitor, and assess early treatment. BioMark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc. Biomark Diagnostics operates under Diagnostics Research classification in the United States and is traded on OTC Exchange.Things to note about BioMark Diagnostics performance evaluation
Checking the ongoing alerts about BioMark Diagnostics for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for BioMark Diagnostics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| BioMark Diagnostics generated a negative expected return over the last 90 days | |
| BioMark Diagnostics has high historical volatility and very poor performance | |
| BioMark Diagnostics has some characteristics of a very speculative penny stock | |
| BioMark Diagnostics has accumulated 96.3 K in total debt. BioMark Diagnostics has a current ratio of 0.34, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist BioMark Diagnostics until it has trouble settling it off, either with new capital or with free cash flow. So, BioMark Diagnostics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like BioMark Diagnostics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for BioMark to invest in growth at high rates of return. When we think about BioMark Diagnostics' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 43.93 K. Net Loss for the year was (1.45 M) with profit before overhead, payroll, taxes, and interest of 43.93 K. | |
| BioMark Diagnostics has accumulated about 364.96 K in cash with (1.2 M) of positive cash flow from operations. | |
| Roughly 55.0% of the company shares are held by company insiders |
- Analyzing BioMark Diagnostics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BioMark Diagnostics' stock is overvalued or undervalued compared to its peers.
- Examining BioMark Diagnostics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating BioMark Diagnostics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of BioMark Diagnostics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of BioMark Diagnostics' pink sheet. These opinions can provide insight into BioMark Diagnostics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for BioMark Pink Sheet analysis
When running BioMark Diagnostics' price analysis, check to measure BioMark Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioMark Diagnostics is operating at the current time. Most of BioMark Diagnostics' value examination focuses on studying past and present price action to predict the probability of BioMark Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioMark Diagnostics' price. Additionally, you may evaluate how the addition of BioMark Diagnostics to your portfolios can decrease your overall portfolio volatility.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |